February 2018: Corion Biotech Patent for the Treatment of Epithelial Tumors by a Placental Mesenchymal Cells-derived biological now granted in Japan!
January 2018: Corion Biotech Granted Patent in the USA for the treatment of Epithelial Tumors by a Placental Mesenchymal Cells-derived biological.
Corion Biotech to Present at Health Tech Summit Lausanne on June 21-22, 2016
Corion Biotech Granted Patent in Europe for the Treatment of Preeclampsia with a Placenta-derived biological.
At Corion Biotech S.r.l. we are committed to develop innovative therapeutic solutions for Women's health. Our technology is based on a specific cell population derived from the human term placenta known as Placental Mesenchymal Stromal Cells (hPDMSCs).
By our property technology, we exploit the unique PDMSCs's therapeutic abilities in-vitro to develop our "Cell Therapy without Cells".
CELL THERAPY WITHOUT CELLS: THE INNOVATIVE APPROACH BY CORION BIOTECH
A cell therapy based on PDMSCs-derived biological cocktails instead of a direct administration of living cells to the patient is a totally new approach which maintains the effectiveness of cell therapy avoiding the risk of direct administration of living allogenic cells.
We strongly believe that our approach is the most ethical, safe and effective solution present in the Advanced Therapy Medicinal Products panorama.